Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/13/2025 | $10.00 | Buy | H.C. Wainwright |
3/7/2025 | $15.00 | Sector Outperform | Scotiabank |
11/25/2024 | $24.00 → $5.00 | Buy → Neutral | BofA Securities |
10/24/2024 | $20.00 | Buy | UBS |
10/1/2024 | $25.00 | Outperform | Wedbush |
9/25/2024 | $21.00 | Buy | Truist |
7/25/2024 | $24.00 | Buy | BofA Securities |
5/9/2024 | Overweight | Cantor Fitzgerald |
8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)
8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)
8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)
Updated interim results with an additional ~16 weeks of follow-up on nine patients in Cohort 1 (2.5 mCi) and Cohort 2 (5.0 mCi) and initial safety findings in an additional 33 patients treated in Cohort 2 from the ongoing Phase 1/2a study were presented[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities and no discontinuations due to adverse events observed among a total of 42 patients who received at least one treatmentFour of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. Three of those patients experienced confirmed response and remained in response. One new first response is subject
Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of dose-finding for [212Pb]VMT-α-NET[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested Three of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. First responses for two patients occurred after end of treatment period and are subject to confirmation, in addition to the previously reported patient with confirmed response who remains in response The five other patients in Coh
SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that an abstract on updated interim results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET (NCT05636618) has been accepted as a poster presentation at the ASCO Gastrointestinal Cancers Symposium (ASCO-GI) taking place on January 23-25, 2025 in San Francisco, CA. The poster presentation entitled "Interim Safety and Efficacy data of [212Pb]VMT-α-NET in Somatostatin Receptor 2 (SSTR2) Expressing Neuroendocrine Tumors (NETs)" will
SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)
SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)
SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)
H.C. Wainwright initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $10.00
Scotiabank initiated coverage of Perspective Therapeutics with a rating of Sector Outperform and set a new price target of $15.00
BofA Securities downgraded Perspective Therapeutics from Buy to Neutral and set a new price target of $5.00 from $24.00 previously
SEATTLE, July 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2025 taking place October 17 to 21, 2025 in Berlin, Germany. ESMO plans to release further details for regular abstracts on October 13, 2025. PresenterAbstract TitlePresentation DetailsThorvardur Halfdanarson, Mayo Clinic Comprehensive Cancer Center[212Pb]VMT-α-NET targeted alpha-particle ther
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 23, 2025 /PRNewswire/ -- USA News Group News Commentary – Cancer diagnoses are climbing fastest among younger women, sparking alarm that looming cuts to U.S. research budgets could stall progress in prevention and treatment. Adding to the strain, federal and state regulators are re‑examining mRNA vaccines, creating a cloud of uncertainty over future cancer‑funding priorities. Yet even amid this policy turbulence, a new wave of oncology innovators is lining up near‑term milestones that could reshape the landscape—led by Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Cue Biopharma, Inc. (NASDAQ:CUE)
SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that it will report its second quarter 2025 financial results and provide a business update on Wednesday, August 13, 2025 before the market opens. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases. About Perspective Therapeutics, Inc.Perspective Therapeutics, Inc. is a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body. The Com
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs,
SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the appointment of Juan Graham as the Company's Chief Financial Officer (CFO), effective as of January 6, 2025. In connection with the transition, Jonathan Hunt will no longer serve as CFO but will continue serving as the Company's Chief Accounting Officer (CAO). "In less than 18 months, Perspective has delivered initial clinical data for two new potential medicines based on its next generation targeted radiopharmaceutical technology platform,